论文部分内容阅读
目前小细胞肺癌的化疗主要为环磷酰胺(CTX)和长春新碱(VCR)两药与其它药物如卡氮芥(lomustine,CCNU),鬼臼乙叉甙(etoposide),甲氨喋呤(MTX)或阿霉素(ADM)的联合化疗,局限期患者两年无瘤生存率为7～26％。 874例中男性631例,女性243例.年龄小于60岁424例,61～70岁450例,健康状况:0～1级558例,2级168例,3～4级147例:全组局限期443例,广泛期431例;组织学诊断按世界卫生组织所订标准,经两个医院的病理学者诊断。治疗前作一般检查.有症状者做脑扫描,经各种检查后作临床分期。
The current chemotherapy for small cell lung cancer is mainly cyclophosphamide (CTX) and vincristine (VCR) and other drugs such as lomustine (CCNU), etoposide, methotrexate ( Combination chemotherapy with MTX) or adriamycin (ADM) resulted in a 2-year disease-free survival rate of 7-26% in patients with localization. Among the 874 cases, there were 631 males and 243 females. There were 424 younger than 60 years old, 450 younger people between 61 and 70 years old, and his health status was 558 to 1-5, 168 to 2 and 147 to 147. There were 443 cases in a limited period and 431 cases in an extensive period; histological diagnosis was diagnosed by the pathologists of both hospitals according to the standards set by the World Health Organization. General examination before treatment. Symptoms of the brain scan, after a variety of tests for clinical staging.